Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSL-DXR-DR5
- Development stage
- Preclinical
- Lead developer
- University at Buffalo
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**SSL-DXR-DR5** is an experimental sterically stabilized, doxorubicin-loaded immunoliposome covalently decorated with the DR5 agonist monoclonal antibody AMG655. The construct is intended to increase intratumoral retention and delivery of doxorubicin while selectively engaging death receptor 5 to activate extrinsic apoptosis. It was evaluated preclinically in pancreatic cancer cell-line xenografts and patient-derived xenograft models, including in combination with sonic hedgehog pathway inhibitor tumor priming. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/78/13_Supplement/3704/627971/Abstract-3704-Efficacy-of-DR5-targeted))
- Other names
- SSL-DXR-DR5 immunoliposomesSSL-DXR-DR-5 immunoliposomesSSL-DXR-DR 5 immunoliposomes
02
Targets
DNATOP2A (DNA topoisomerase II)TNFRSF10B (DR5)
Beyond the preview
Go deeper on SSL-DXR-DR5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSL-DXR-DR5.